Viracta Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference
Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology firm, announced that CEO Dr. Ivor Royston will present at the 11th Annual SVB Leerink Global Healthcare Conference on February 17, 2022, at 5:00 p.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology firm, announced that CEO Dr. Ivor Royston will present at the 11th Annual SVB Leerink Global Healthcare Conference on February 17, 2022, at 5:00 p.m. ET. The presentation can be accessed via webcast on the Investors section of Viracta's website, with an archive available for 60 days. Viracta focuses on virus-associated malignancies, evaluating its investigational drug nanatinostat in pivotal trials for Epstein-Barr virus-positive lymphoma and other cancers.
Details
News Market Reaction – VIRX
The recorded move for VIRX in the trading session of this news was +9.12%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, Feb. 10, 2022 /PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that Dr. Ivor Royston, the company's President and Chief Executive Officer, is scheduled to present at the 11th Annual SVB Leerink Global Healthcare Conference, on Thursday, February 17, 2022, at 5:00 p.m. ET.
A webcast of the presentation will be available on the Investors section of the Viracta website under "Events and Webcasts" at https://viracta.investorroom.com/events-and-webcasts. The webcast will be archived for 60 days.
About Viracta Therapeutics, Inc.
Viracta is a precision oncology company targeting virus-associated malignancies. Viracta's proprietary investigational drug, nanatinostat, is currently being evaluated in combination with the antiviral agent valganciclovir as an oral combination therapy, Nana-Val, in a pivotal Phase 2 clinical trial for Epstein-Barr virus-positive (EBV+) lymphoma and a Phase 1b/2 trial in patients with EBV+ nasopharyngeal carcinoma and other EBV+ solid tumors. Viracta is also pursuing the application of its inducible synthetic lethality approach in other virus-related cancers.
For additional information please visit www.viracta.com.
Investor Relations Contact:
Ashleigh Barreto
Head of Investor Relations & Corporate Communication
Viracta Therapeutics, Inc.
abarreto@viracta.com
SOURCE Viracta Therapeutics, Inc.
View original content to download multimedia:https://www.prnewswire.com/news-releases/viracta-therapeutics-to-present-at-the-11th-annual-svb-leerink-global-healthcare-conference-301479835.html
SOURCE Viracta Therapeutics, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.